# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...
Stifel analyst Mathew Blackman reiterates ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $8 to $9.
ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0....
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...